GSK Gsk Plc

TIDMGSK

RNS Number : 8440X

GlaxoSmithKline PLC

06 May 2021

GlaxoSmithKline plc

GSK announces changes to its Board and Committees

GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021.

As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee.

In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee.

Note

 
 1.   From 6 May 2021 the Board of GSK comprises 
      Sir Jonathan Symonds   Non-Executive Chairman 
       Emma Walmsley          Chief Executive Officer 
       Iain Mackay            Chief Financial Officer 
       Dr Hal Barron          Chief Scientific Officer and President, 
       Vindi Banga            R&D 
       Charles Bancroft       Senior Independent Non-Executive Director 
       Dr Anne Beal           Independent Non-Executive Director 
       Dr Vivienne Cox        Independent Non-Executive Director 
       Lynn Elsenhans         Independent Non-Executive Director 
       Dr Jesse Goodman       Independent Non-Executive Director 
       Dr Laurie Glimcher     Independent Non-Executive Director 
       Urs Rohner             Independent Non-Executive Director 
                              Independent Non-Executive Director 
 

V A Whyte

Company Secretary

6 May 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABLGDUCSGDGBL

(END) Dow Jones Newswires

May 06, 2021 12:51 ET (16:51 GMT)

Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024